Company profile
Kodiak Sciences Inc.
NASDAQ:KODBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tarcocimab Tedromer | phase3 | — | 7 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06990399 | phase3 | recruiting | 2025-07-30 | 2027-04-01 | Kodiak Sciences Inc | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK |
| NCT06996080 | phase3 | recruiting | 2025-07-16 | 2027-02-01 | Kodiak Sciences Inc | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE |
| NCT04964089 | phase3 | completed | 2021-06-23 | 2023-03-28 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) |
| NCT05066230 | phase3 | terminated | 2021-09-07 | 2023-08-03 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) |
| NCT04049266 | phase2_3 | terminated | 2019-10-08 | 2021-11-17 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. |
FDA applications (0)
No records yet.